Analysts’ Recent Ratings Changes for Regeneron Pharmaceuticals (REGN)

Several brokerages have updated their recommendations and price targets on shares of Regeneron Pharmaceuticals (NASDAQ: REGN) in the last few weeks:

  • 1/7/2019 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 1/7/2019 – Regeneron Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen Inc. They now have a $385.00 price target on the stock.
  • 1/5/2019 – Regeneron Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “While Regeneron’s key growth driver, Eylea continues to drive sales and label expansion into additional indications has further boosted growth, the company is highly dependent on Eylea for growth. Competition from other drugs like Novartis/Roche’s Lucentis and Roche’s Avastin (off-label) loom large on Eylea. Sales of Praluent have failed to impress. Nevertheless, the company is working to expand Dupixent’s label further in several other indications. This should diversify the company’s revenue base and reduce dependence on Eylea.  In September 2018, the FDA approved its immuno-oncology therapy, Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Shares have outperformed the industry in the past six months.”
  • 1/4/2019 – Regeneron Pharmaceuticals was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating. They now have a $461.00 price target on the stock.
  • 12/15/2018 – Regeneron Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 12/13/2018 – Regeneron Pharmaceuticals was upgraded by analysts at Goldman Sachs Group Inc from a “neutral” rating to a “conviction-buy” rating.
  • 12/11/2018 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/7/2018 – Regeneron Pharmaceuticals was given a new $483.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 12/2/2018 – Regeneron Pharmaceuticals was given a new $440.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/23/2018 – Regeneron Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 11/16/2018 – Regeneron Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

NASDAQ:REGN opened at $404.99 on Monday. Regeneron Pharmaceuticals Inc has a one year low of $281.89 and a one year high of $416.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. The stock has a market cap of $43.24 billion, a P/E ratio of 30.20, a price-to-earnings-growth ratio of 1.72 and a beta of 1.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping the consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The business had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.64 billion. During the same quarter in the previous year, the firm posted $3.99 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 10.8% on a year-over-year basis. Research analysts anticipate that Regeneron Pharmaceuticals Inc will post 18.88 EPS for the current fiscal year.



In other news, VP Christopher R. Fenimore sold 1,848 shares of the company’s stock in a transaction that occurred on Thursday, December 20th. The shares were sold at an average price of $358.97, for a total value of $663,376.56. Following the transaction, the vice president now owns 9,871 shares in the company, valued at $3,543,392.87. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 1,791 shares of the company’s stock in a transaction that occurred on Thursday, January 10th. The stock was sold at an average price of $410.00, for a total transaction of $734,310.00. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $5,786,740. The disclosure for this sale can be found here. Insiders have sold 3,645 shares of company stock worth $1,399,980 in the last three months. 12.42% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Capital World Investors raised its holdings in shares of Regeneron Pharmaceuticals by 5.3% during the third quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock valued at $2,579,522,000 after purchasing an additional 322,051 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after purchasing an additional 75,868 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock valued at $2,325,220,000 after purchasing an additional 75,868 shares during the last quarter. FMR LLC raised its holdings in shares of Regeneron Pharmaceuticals by 17.0% during the third quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock valued at $2,026,867,000 after purchasing an additional 728,104 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its holdings in shares of Regeneron Pharmaceuticals by 1.2% during the third quarter. Loomis Sayles & Co. L P now owns 3,346,280 shares of the biopharmaceutical company’s stock valued at $1,352,031,000 after purchasing an additional 41,138 shares during the last quarter. Hedge funds and other institutional investors own 67.20% of the company’s stock.

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: How to calculate compound interest

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply